European Commission (EC) extends approval for daratumumab to include myeloma patients who have received at least one prior therapy
European Commission (EC) has granted approval daratumumab for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with myeloma who have received at least one prior therapy.